On March 5, 2020, the Board of Directors (the “Board”) of SIGA Technologies, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, determined that it will nominate Jaymie Durnan to serve as a director at the Company’s 2020 annual meeting of stockholders (the “2020 Annual Meeting”).

Mr. Durnan serves as the Deputy Assistant to the Director for Strategic Initiatives at the Massachusetts Institute of Technology Lincoln Laboratory, the nation’s premiere federally funded research, development and prototyping center, since September 2015. A member of the New York State Bar, he has served from approximately 1992 through 1999 as a Senior Vice President and Special Counsel at MacAndrews & Forbes Holding Inc. Mr. Durnan has also served as a Product Line Manager at BAE Systems; a Partner at Radius Capital Partners, a private investment firm; and, as the Managing Member of Woodbury Hill Partners, LLC, a strategic advisory firm counseling companies from startup to the Fortune 200. His government service includes as a member of the Federal Senior Executive Service, where he served as the Special Assistant (Chief of Staff) to the Deputy Secretary of Defense and a Special Assistant to the Secretary and Deputy Secretary of Defense in the President George W. Bush administration. He also served as the Senior Advisor to the Chief Technology Officer and the Assistant Secretary of Defense for Research and Engineering in the Department of Defense from March 2009 to August 2013. A retired naval officer, he served as an aircraft carrier-based naval aviator; a strategic planner in the Office of the Secretary of Defense; an operations analyst on the staff of the Chief of Naval Operations; an Aide to the Chief of Naval Operations; a member of staff of the Chairman of the Joint Chiefs of Staff supporting arms control negotiations; and a Military Social Aide to the President of the United States. For his service, Mr. Durnan has received some of the highest Defense Department non-combat awards including, the Department of Defense Medal for Distinguished Public Service, and the Navy Distinguished Public Service Award presented by the Secretary of the Navy to a civilian for specific courageous or heroic acts or exceptionally outstanding service of substantial and long-term benefit to the Navy, Marine Corps or Department of the Navy. Mr. Durnan has served as a director or trustee for MacAndrews & Forbes Worldwide Corp.; Swift Prepaid Solutions; kSARIA Corp.; Orthozon Technologies; Defensewerx; Antioch New England University; and, Unity College. He is the Chairman of the Andrew W. Marshall Foundation. He is a graduate of the United States Naval Academy, Georgetown University, and the Georgetown University School of Law.

On March 5, 2020, the Company and Jeffrey B. Kindler agreed that Mr. Kindler will not stand for re-election to the Board at the Company’s 2020 Annual Meeting. This agreement is not the result of any disagreement with the Company relating to the Company’s operations, policies or practices. Mr. Kindler will continue to serve on the Board until his term expires at the conclusion of the 2020 Annual Meeting.

About SIGA TECHNOLOGIES, INC. (OTCMKTS:SIGA)

SIGA Technologies, Inc. (SIGA) is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. Tecovirimat is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). Tecovirimat is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. Tecovirimat has Orphan Drug designation for both the treatment and prevention of smallpox, and the treatment of orthopoxvirus infections (vaccinia, variola, monkeypox and cowpox). The Company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture Tecovirimat. The Company also has a lead pre-clinical drug candidate with activity against approximately four serotypes of the dengue virus.